New pathways on PharmGKB: Sorafenib PK and PD
We have added two new pathways: Sorafenib PK and PD pathways to our pathway collections.
Sorafenib (Nexavar, BAY 43-9006) is a cancer drug used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma. It blocks tumor cell proliferation and angiogenesis by targeting various types of serine/threonine and receptor